DECK DECK

Name: DECK Crucible Score
Creator: Kaladin Capital Intelligence

UnknownUnknownN/A📅 Scored April 7, 2026

Price at analysis: $100.05

Crucible Score

79.9

A-

Quality × Value Composite

KQI — Quality

81.0

A-

Fundamental Quality Index

KVI — Value

78.5

B+

Valuation Attractiveness Index

Crucible Verdict — DECK

Deck Therapeutics (DECK) delivers exceptional earnings consistency with a 94% beat rate and strong financial quality scores, yet trades at a 20% discount to fair value despite solid fundamentals across most dimensions. The company's weakest links are diversification and market position, both scoring in the low 70s. DECK presents a quality play trading below intrinsic value with limited downside protection.

— Kal, Kaladin Capital Intelligence

◆ KQI Quality Dimensions

Financial Quality

91.5

Growth Profile

79.2

Moat Durability

75.9

Management Effectiveness

76.6

Diversification & Resilience⚠

68.0

Market Position

72.0

Weakest dimension: Diversification & Resilience (68.0)

◆ KVI Value Dimensions

DCF Margin of Safety

61.1

FCF Yield & Cash Returns

70.8

Relative Valuation

93.7

Growth-Adjusted Value

95.0

Historical Valuation

94.5

Macro Context

55.8

◆ DCF Valuation Scenarios

Bear Case

$78.52

Base Case

$119.87

Bull Case

$175.43

Price at Analysis

$100.05

Scenario	Fair Value	Rev CAGR (5yr)	Terminal Margin	WACC
🔴 Bear	$78.52	6.0%	20.0%	10.9%
🟢 Base	$119.87	9.0%	23.0%	10.3%
🟢 Bull	$175.43	12.0%	26.0%	9.8%

Key Assumptions: Revenue grew at a 5-year CAGR of ~14% with operating margins expanding from ~20% to ~24%; base case assumes moderation to 9% revenue CAGR as DECK matures with margins stabilizing near 23%. WACC derived using CAPM with 4.39% risk-free rate, 1.16 beta, and 5.5% ERP yielding ~10.8% cost of equity, adjusted slightly across scenarios. FCF conversion remains strong given low capex intensity (~1.8% of revenue) and modest working capital needs.

◆ Financial Snapshot

Profitability

Gross Margin57.5%

Operating Margin23.8%

Net Margin19.3%

ROIC34.3%

ROE39.9%

Balance Sheet

Balance SheetD/E: 0.13*, CR: 2.86* (* = TTM)

Cash ConversionFCF/EPS: 0.89x

Capital IntensityCapex/Rev: 1.7%

Altman Z-Score9.67 (Safe)

Piotroski F-Score4/9 (Mixed)

Growth

Revenue CAGR18.3% CAGR

Earnings CAGR26.1% CAGR

Growth ConsistencyCV: 0.71

Segment Breadth4/4 growing (100%)

Quarterly TrendRev↘+6%, Margin↑, Cash↓, WC↓, Exp↓

Earnings CredibilityConsistent Beater

◆ Analyst Consensus & Leadership

Leadership & Governance

CEOZohar Zuckerman · 3 years

CEO Ownership< 1%

Compensation89% performance-based

Insider ActivitySelling

Capital AllocationROIC 34.3% vs WACC 1.0%

Earnings Beat Rate94% (21/22)

◆ Related Companies in Our Universe

Other Unknown companies scored by the Crucible:

ADBE81.8A-NICE80.7A-INTU79.9A-EXEL78.3A-MTCH78.2A-TTD78.0B+PCTY75.8B+

Methodology All Scores Crucible Briefs Performance @KaladinCI

Analysis conducted April 7, 2026 based on most recent SEC filings. Updated quarterly, after new SEC filings.

Point-in-time fundamental analysis. Not investment advice. Scores reflect company quality and valuation at time of analysis and may not reflect current market conditions.